Sign up USA
Proactive Investors - Run By Investors For Investors

Marinus Pharmaceuticals shares surge on Nasdaq on successful clinical trial results

The candidate is being used to treat CDKL5 - a rare genetic disorder
Marinus Pharmaceuticals shares surge on Nasdaq on successful clinical trial results
It mainly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro developmental impairment

Shares in Marinus Pharmaceuticals (NASDAQ:MRNS) added over 46% on Nasdaq to $4.57 as it posted positive top-line data from a phase 2 study assessing orphan drug-tagged ganaxolone.

The candidate is being used to treat  CDKL5  - a rare genetic disorder, which is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome.

It mainly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro‑developmental impairment.

Dr Orrin Devinsky, the principal investigator in the current study, said: “I am impressed with the magnitude of seizure reduction and gain in seizure-free days seen with ganaxolone treatment in children with this highly refractory epilepsy.

"The durable anti-epileptic effect seen in several children distinguishes ganaxolone’s efficacy from the more than 20 currently available anti-epileptic drugs that provide limited seizure control lasting a few weeks to months.

"When treating children with the severest forms of epilepsy such as CDKL5 disorder, there is a desperate need for new drugs that are well-tolerated, efficacious and easy to administer with no need for special monitoring.

"With no other treatment showing this degree of promise, I am excited to lead the effort to advance ganaxolone into potentially the first, late-stage clinical trial in children with CDKL5 disorder.”

View full MRNS profile View Profile

Marinus Timeline

Related Articles

biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use